ArticleBMC medicine2016
Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection.
Article in BMC medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Gut Microbiota in the Pathogenesis of Ankylosing Spondylitis (AS), and the Effect of Fecal Microbiota Transplantation on Gut Microbiota, Gut Wall Inflammation and Clinical Activity of AS
Effects of Probiotic Treatment on Body Composition and Insulin Resistance in Patients With Obesity Grade II and III and Its Association With Changes in Intestinal Microbiota
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome.BMC gastroenterology · 2024Pooled it
- Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials.Frontiers in medicine · 2022Pooled it
- Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis.Journal of Crohn's & colitis · 2025Trial
- Fecal microbiota transplantation for the maintenance of remission in patients with ulcerative colitis: A randomized controlled trial.World journal of gastroenterology · 2023Trial
- Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan.BMC gastroenterology · 2022Trial
- Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals.Scientific reports · 2020Trial
- Fecal microbiota transplantation in puppies with canine parvovirus infection.Journal of veterinary internal medicine · 2018Trial
- Trial
- Comparison of Mucosal and Faecal Microbiomes in Patients With Cirrhosis.Gastroenterology research and practice · 2026Article
- Gut microbiota in obesity management: from microbial clocks to precision microbial therapies.Frontiers in cellular and infection microbiology · 2026Review
- Fecal microbiota transplantation: from empirical remedy to precision medicine.Frontiers in microbiomes · 2026Review
- A review of engraftment assessments following fecal microbiota transplant.Gut microbes · 2025Review
- Characterization of fecal deglucuronidation activity in healthy subjects and in patients treated with fecal microbiota transplantation.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Impact of fecal microbiota transplantation in dogs.Frontiers in veterinary science · 2025Article
- Pathogen exclusion from intestinal mucus and antimicrobial susceptibility ofMicrobiome research reports · 2025Article
- Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial.EClinicalMedicine · 2024Article
- Aged oolong tea alleviates dextran sulfate sodium-induced colitis in mice by modulating the gut microbiota and its metabolites.Food chemistry: X · 2024Article
- The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.Frontiers in microbiology · 2023Review
- Intestinal IgA-Coated Bacteria in Healthy- and Altered-Microbiomes (Dysbiosis) and Predictive Value in Successful Fecal Microbiota Transplantation.Microorganisms · 2022Review
- Fecal Microbiota Transplant in Recurrent Clostridium Difficile Infections: A Systematic Review.Cureus · 2022Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI). It restores the disrupted intestinal microbiota and subsequently suppresses C. difficile. The long-term stability of the intestinal microbiota and the recovery of mucosal microbiota, both of which have not been previously studied, are assessed herein. Further, the specific bacteria behind the treatment efficacy are also investigated.
methodsWe performed a high-throughput microbiota profiling using a phylogenetic microarray analysis of 131 faecal and mucosal samples from 14 rCDI patients pre- and post-FMT during a 1-year follow-up and 23 samples from the three universal donors over the same period.
resultsThe FMT treatment was successful in all patients. FMT reverted the patients' bacterial community to become dominated by Clostridium clusters IV and XIVa, the major anaerobic bacterial groups of the healthy gut. In the mucosa, the amount of facultative anaerobes decreased, whereas Bacteroidetes increased. Post-FMT, the patients' microbiota profiles were more similar to their own donors than what is generally observed for unrelated subjects and this striking similarity was retained throughout the 1-year follow-up. Furthermore, the universal donor approach allowed us to identify bacteria commonly established in all CDI patients and revealed a commonly acquired core microbiota consisting of 24 bacterial taxa.
conclusionsFMT induces profound microbiota changes, therefore explaining the high clinical efficacy for rCDI. The identification of commonly acquired bacteria could lead to effective bacteriotherapeutic formulations. FMT can affect microbiota in the long-term and offers a means to modify it relatively permanently for the treatment of microbiota-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.